Anzeige
Mehr »
Donnerstag, 11.09.2025 - Börsentäglich über 12.000 News
Diese Aktie sichert sich Exklusiv-Partnerschaft mit Babcock für Ukraine-Defence - Neubewertung voraus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UCX | ISIN: NL0015002AH0 | Ticker-Symbol: JP7
Tradegate
10.09.25 | 15:50
1,523 Euro
+1,30 % +0,020
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
HAVAS NV Chart 1 Jahr
5-Tage-Chart
HAVAS NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,5091,51113:33
1,5071,51313:29
PR Newswire
177 Leser
Artikel bewerten:
(1)

Havas Health Network Announces Two Senior Strategic Appointments

Christina Stoddard appointed EVP, Head of Strategy, for global flagship clients, and Ayesha Walawalkar named CSO of Havas Lynx UK

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Havas Health Network today announced the appointment of two senior strategic leaders: Christina Stoddard as Executive Vice President, Head of Strategy, where she will lead strategy for global flagship clients, and Ayesha Walawalkar as Chief Strategy Officer for Havas Lynx UK. These hires reflect the network's continued investment in integrated, audience-first thinking to power culturally resonant brand strategy across health and wellness.

Havas Health Logo

"Christina and Ayesha represent the caliber of strategic leadership that defines the future of Havas Health Network, and we're thrilled to welcome them to our leadership team," said Brian Robinson, Global Chief Strategy Officer and Head of Growth, Havas Health Network. "As our network expands and the industry evolves, we're investing in leaders who understand the complexities of health, culture, and data, and can shape that knowledge into market-transforming work."

Christina Stoddard has been appointed EVP, Head of Strategy focusing on global integrated client work, leading strategy across all audiences, including HCP, patient, and consumer. Stoddard brings a rare combination of consumer and health experience, having led strategic work for global brands including Milk, TRESemmé, and Snickers, as well as three Super Bowl campaigns. Most recently, she served as Head of Strategy at 21Grams, where she helped drive the agency's rapid growth, particularly in the rare disease space. A recognized leader in healthcare marketing, she was named to MM+M's 40 Under 40 for her industry impact.

Over the course of her career, Stoddard has built a reputation for blending creativity with business rigor, and for pushing brands to connect with audiences in more human, more meaningful ways. She joins the leadership team and will work in close collaboration with cross-disciplinary teams to deepen audience insight and accelerate innovation across the business.

Ayesha Walawalkar joins as Chief Strategy Officer for Havas Lynx UK, where she will work alongside senior leadership to define and drive the next chapter of strategic growth. With more than 30 years of experience, she has led global brand strategies across both health and consumer sectors. Prior to Havas, she served as CSO at MullenLowe Global, where she led strategy for clients including Unilever, Kimberly-Clark, and Bayer Consumer Health.

Her work has received accolades from Cannes Lions, D&AD, Clio, Effie, and WARC. She has also been a longtime champion of equity and inclusion, most notably through IPG's "Invisible Powerhouse" initiative, which helped shape global ageism guidance for the Unstereotype Alliance.

Both leaders will join the Havas Health Network Global Strategy Leadership Team, where they will help shape the network's next evolution of strategic vision, rooted in integrated thinking across audiences, categories, and cultures.

ABOUT HAVAS HEALTH NETWORK
Havas Health Network unites Havas Life, Havas Lynx, and Jacques, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Network. The network's approach is centered around making a meaningful difference and has the talent, tenacity, and technology that health companies, brands, and people need to thrive in today's world. For more information, visit www.HavasHealth.com

Logo - https://mma.prnewswire.com/media/2763952/Havas_Health_Network_Havas_Health_Network_Announces_Two_Senior_S.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/havas-health-network-announces-two-senior-strategic-appointments-302547888.html

© 2025 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.